Claims Are Construed In Zolmitriptan Dispute

Morris James LLP
Contact

Impax Laboratories, Inc., et al. v. Lannett Holding Inc., et al., C.A. No. 14-984 - RGA, December 1, 2015.

Andrews, J.  Claim construction opinion issues regarding three terms from two patents.  A Markman hearing took place on November 16, 2015

The disputed technology relates to pharmaceutical formulations. The following terms were considered:

  1. “preambles”
  2. “zolmitriptan”
  3. “buffer”, “buffered”, “in a buffer”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morris James LLP | Attorney Advertising

Written by:

Morris James LLP
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Morris James LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide